Apontis Pharma AG
XETRA:APPH
Apontis Pharma AG
Other Operating Expenses
Apontis Pharma AG
Other Operating Expenses Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
Company | Other Operating Expenses | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
---|---|---|---|---|---|---|
A
|
Apontis Pharma AG
XETRA:APPH
|
Other Operating Expenses
-€9.6m
|
CAGR 3-Years
-17%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
![]() |
ATAI Life Sciences NV
NASDAQ:ATAI
|
Other Operating Expenses
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
![]() |
Bayer AG
XETRA:BAYN
|
Other Operating Expenses
-€4B
|
CAGR 3-Years
3%
|
CAGR 5-Years
-9%
|
CAGR 10-Years
-61%
|
|
![]() |
Merck KGaA
XETRA:MRK
|
Other Operating Expenses
-€568m
|
CAGR 3-Years
-40%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
-3%
|
|
![]() |
Dermapharm Holding SE
XETRA:DMP
|
Other Operating Expenses
-€168.1m
|
CAGR 3-Years
-14%
|
CAGR 5-Years
-14%
|
CAGR 10-Years
N/A
|
|
![]() |
PharmaSGP Holding SE
XETRA:PSG
|
Other Operating Expenses
-€6.9m
|
CAGR 3-Years
-2%
|
CAGR 5-Years
-5%
|
CAGR 10-Years
N/A
|
Apontis Pharma AG
Glance View
APONTIS PHARMA AG engages in the development, promotion, and sale of single pills and other pharmaceutical products. The company is headquartered in Monheim Am Rhein, Nordrhein-Westfalen and currently employs 176 full-time employees. The company went IPO on 2021-05-11. The firm focuses on the commercialization of pharmaceutical products to General Practitioners and engages in the marketing and sale of medical drugs for indication fields of internal medicine in Germany.
See Also
What is Apontis Pharma AG's Other Operating Expenses?
Other Operating Expenses
-9.6m
EUR
Based on the financial report for Dec 31, 2023, Apontis Pharma AG's Other Operating Expenses amounts to -9.6m EUR.
What is Apontis Pharma AG's Other Operating Expenses growth rate?
Other Operating Expenses CAGR 3Y
-17%
Over the last year, the Other Operating Expenses growth was 2%. The average annual Other Operating Expenses growth rates for Apontis Pharma AG have been -17% over the past three years .